✦ LIBER ✦

The Pathogenesis of Granulopoietic Hyperplasia in Chronic Myeloid Leukaemia and the Humoral Regulating Factors: A Hypothesis

✍ Scribed by Pedersen, Bent

Book ID: 114788711
Publisher: Wiley (Blackwell Publishing)
Year: 2009
Weight: 399 KB
Volume: 14
Category: Article
ISSN: 0036-553X
DOI: 10.1111/j.1600-0609.1975.tb00302.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Pathogenesis of Spleen Mediated Phen

The Pathogenesis of Spleen Mediated Phenomena in Chronic Myeloid Leukaemia and Agnogenic Myeloid Metaplasia: A Non Abscopal Mechanism

✍ ADLER, SOLOMON S. 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 506 KB

Possible significance of Ph, Zinc and BC

Possible significance of Ph, Zinc and BCR-ABL chimaerism in the pathogenesis of chronic myeloid leukaemia

✍ I.M. Jibrin 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 400 KB

Chronic inflammation in the pathogenesis

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia

✍ B. Fibbi; G. Penna; A. Morelli; L. Adorini; M. Maggi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB

A potential role for PRDM12 in the patho

A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion

✍ Reid, A G; Nacheva, E P 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 123 KB

Significance of haemoglobin-S in the pat

Significance of haemoglobin-S in the pathogenesis of hyperleucocytic syndromes in Nigerian patients with chronic myeloid leukaemia

✍ SG Ahmed; UA Ibrahim 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 445 KB

Oral idarubicin in the treatment of acut

Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia

✍ S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per